The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Eli Lilly said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials.
The results are an early sign of hope for the estimated 80 million patients in the U.S. suffering from OSA, which refers to interrupted breathing during sleep due to narrowed or blocked airways. Around 20 million of those people have moderate-to-severe forms of the disease, but 85% of OSA cases go undiagnosed, according to Eli Lilly., loud snoring and can contribute to serious complications, including hypertension, stroke and heart failure.
Zepbound led to an average AHI reduction of 25.3 events per hour at 52 weeks, regardless of whether a patient discontinued the treatment. That compares to an average reduction of 5.3 events per hour for the placebo. Eli Lilly's drug led to an average AHI reduction of 29.3 events per hour at 52 weeks, regardless of whether a patient discontinued the treatment. That compares to an average reduction of 5.5 events per hour for the placebo.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Lire la suite »
Eli Lilly Warns That 2 Insulin Products Will Be in Short SupplyDrugmaker Eli Lilly & Co is announcing a temporary shortage of two of its insulin products.
Lire la suite »
Eli Lilly warns 2 of its insulin products may be out of stockThe shortage applies to the company's 10 mL vials of Humalog and Insulin Lispro Injection medications.
Lire la suite »
Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker saysZepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday.
Lire la suite »
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughtsThe review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly’s Zepbound and…
Lire la suite »